{"publication_id":"ea8f0afd-dc89-418d-b158-6e496c6cfe3b","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","doi":"10.1161/circulationaha.122.060511","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","doi":"10.1038/s41591-022-01971-4","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction","doi":"10.1161/circulationaha.120.050391","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology","doi":"10.1038/s42255-023-00943-3","risk_of_bias":"not appraised in public sidecar","directness":"primary"}]}